High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial (Q33434270)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

Michael Pfreundschuh

17

object named as

Michael Pfreundschuh

0 references

Stephan Stilgenbauer

9

object named as

Stephan Stilgenbauer

0 references

11

object named as

Peter Hau

0 references

Matthias Edinger

object named as

Matthias Edinger

12

0 references

author name string

Gerald Illerhaus

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Benjamin Kasenda

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Gabriele Ihorst

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Gerlinde Egerer

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Monika Lamprecht

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Ulrich Keller

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Hans-Heinrich Wolf

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Carsten Hirt

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Mascha Binder

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Peter Hau

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Norbert Frickhofen

13

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Martin Bentz

14

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Robert Möhle

15

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Alexander Röth

16

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Louisa von Baumgarten

18

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Martina Deckert

19

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Claudia Hader

20

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Heidi Fricker

21

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Elke Valk

22

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Elisabeth Schorb

23

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Kristina Fritsch

24

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jürgen Finke

25

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

13 July 2016

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

The Lancet. Haematology.

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

e388-97

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Trends in survival from primary central nervous system lymphoma, 1975-1999: a population-based analysis

1 reference

https://api.crossref.org/works/10.1016/S2352-3026(16)30050-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis

1 reference

https://api.crossref.org/works/10.1016/S2352-3026(16)30050-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Rising incidence of primary central nervous system lymphoma in Kumamoto, Japan

1 reference

https://api.crossref.org/works/10.1016/S2352-3026(16)30050-3

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.

1 reference

https://api.crossref.org/works/10.1016/S2352-3026(16)30050-3

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma

1 reference

https://api.crossref.org/works/10.1016/S2352-3026(16)30050-3

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system

1 reference

https://api.crossref.org/works/10.1016/S2352-3026(16)30050-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma--a long-term follow-up study

1 reference

https://api.crossref.org/works/10.1016/S2352-3026(16)30050-3

7 January 2021

based on heuristic

inferred from DOI database lookup

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

1 reference

https://api.crossref.org/works/10.1016/S2352-3026(16)30050-3

7 January 2021

based on heuristic

inferred from DOI database lookup

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016/S2352-3026(16)30050-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

https://api.crossref.org/works/10.1016/S2352-3026(16)30050-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma.

1 reference

https://api.crossref.org/works/10.1016/S2352-3026(16)30050-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1016/S2352-3026(16)30050-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires

1 reference

https://api.crossref.org/works/10.1016/S2352-3026(16)30050-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016/S2352-3026(16)30050-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.

1 reference

https://api.crossref.org/works/10.1016/S2352-3026(16)30050-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Estimation of failure probabilities in the presence of competing risks: new representations of old estimators

1 reference

https://api.crossref.org/works/10.1016/S2352-3026(16)30050-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A note on quantifying follow-up in studies of failure time

1 reference

https://api.crossref.org/works/10.1016/S2352-3026(16)30050-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Primary CNS lymphoma

1 reference

https://api.crossref.org/works/10.1016/S2352-3026(16)30050-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10.

1 reference

https://api.crossref.org/works/10.1016/S2352-3026(16)30050-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Delayed neurotoxicity in primary central nervous system lymphoma

1 reference

https://api.crossref.org/works/10.1016/S2352-3026(16)30050-3

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial

1 reference

https://api.crossref.org/works/10.1016/S2352-3026(16)30050-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis

1 reference

https://api.crossref.org/works/10.1016/S2352-3026(16)30050-3

7 January 2021

based on heuristic

inferred from DOI database lookup

First-line autologous stem cell transplantation in primary CNS lymphoma.

1 reference

https://api.crossref.org/works/10.1016/S2352-3026(16)30050-3

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group

1 reference

https://api.crossref.org/works/10.1016/S2352-3026(16)30050-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato

1 reference

https://api.crossref.org/works/10.1016/S2352-3026(16)30050-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Upfront thiotepa, busulfan, cyclophosphamide, and autologous stem cell transplantation for primary CNS lymphoma: a single centre experience

1 reference

https://api.crossref.org/works/10.1016/S2352-3026(16)30050-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma.

1 reference

https://api.crossref.org/works/10.1016/S2352-3026(16)30050-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Upfront autologous stem-cell transplantation with melphalan, cyclophosphamide, etoposide, and dexamethasone (LEED) in patients with newly diagnosed primary central nervous system lymphoma

1 reference

https://api.crossref.org/works/10.1016/S2352-3026(16)30050-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Feasibility of BU, CY and etoposide (BUCYE), and auto-SCT in patients with newly diagnosed primary CNS lymphoma: a single-center experience

1 reference

https://api.crossref.org/works/10.1016/S2352-3026(16)30050-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Haematopoietic stem cell transplantation for treatment of primary CNS lymphoma: single-centre experience and literature review.

1 reference

https://api.crossref.org/works/10.1016/S2352-3026(16)30050-3

7 January 2021

based on heuristic

inferred from DOI database lookup

R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma

1 reference

https://api.crossref.org/works/10.1016/S2352-3026(16)30050-3

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma

1 reference

https://api.crossref.org/works/10.1016/S2352-3026(16)30050-3

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose chemotherapy with hematopoietic stem cell transplantation for the treatment of primary central nervous system lymphoma

1 reference

https://api.crossref.org/works/10.1016/S2352-3026(16)30050-3

7 January 2021

based on heuristic

inferred from DOI database lookup

High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial.

1 reference

https://api.crossref.org/works/10.1016/S2352-3026(16)30050-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202).

1 reference

https://api.crossref.org/works/10.1016/S2352-3026(16)30050-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome

1 reference

https://api.crossref.org/works/10.1016/S2352-3026(16)30050-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term survival in patients with newly diagnosed primary central nervous system lymphoma treated with dexamethasone, etoposide, ifosfamide and carboplatin chemotherapy and whole-brain radiation therapy

1 reference

https://api.crossref.org/works/10.1016/S2352-3026(16)30050-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S2352-3026(16)30050-3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33434270&oldid=1536205504"